Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$91K+4.6%
Altimmune logo
AltimmuneALT
$13K+62.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1K0.0%
Wave Life Sciences logo
Wave Life SciencesWVE
$1.63B+36.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$236K+2.6%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemJune 30,2026December 31,2025
Total liabilities720,921656,900
Stockholders’ equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2026 and December 31, 2025; 2,369,797 shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, par value $0.0001 per share authorized: 200,000,000 shares at June 30, 2026 and December 31, 2025; 23,093,974 and 22,842,073 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively22
Additional paid-in-capital2,765,7102,692,280
Accumulated other comprehensive income808873
Accumulated deficit(2,242,796)(2,090,466)
Total stockholders’ equity523,724602,689

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s common stock?
Madrigal Pharmaceuticals, Inc. (MDGL) reported common stock of 200M in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s common stock changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s common stock decreased by 0.0% year-over-year, from 200M to 200M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s common stock?
Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s common stock has grown at a 0.0% compound annual growth rate (CAGR), from 2K to 2K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Madrigal Pharmaceuticals, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude